Evaluation of the effects of Gabapentin vaginal gel on Dyspareunia

Evaluation of the effectiveness of Gabapentin vaginal gel on pain control in patients with Dyspareunia; A double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191106045356N13

Enrollment

Registered

2022-10-31

Start date

2022-10-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspareunia. Dyspareunia

Interventions

Intervention 1: Intervention group: 30 patients with dyspareunia who were treated with 5% gabapentin vaginal gel (gabapentin, hydroxypropyl methylcellulose and carbomer), topical use (vaginal), daily

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: married Suffering from Dyspareunia Insensitivity to gabapentin and vaginal gel base ingredients Not taking vaginal painkillers or systemic gabapentin one week before the start of the study Consent to participate in the study and complete the informed consent form

Exclusion criteria

Exclusion criteria: History of psychiatric diseases Acute and chronic vaginal infection cancer of the female genital tract Pregnancy and breastfeeding

Design outcomes

Primary

Measure	Time frame
NSR Pain Scale. Timepoint: Measurement of NRS scale at the beginning of the study and on days 7, 14, 21 and 28 days after the start of gabapentin gel consumption. Method of measurement: NRS Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Zabihi

Yazd University of Medical Sciences

mzabihi100@gmail.com+98 35 3820 3865

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026